Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation.
Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation.
复制标题
DOI：
10.1172/jci.insight.168221
复制
发表时间：
2023-05-22
期刊：
影响因子：
8
通讯作者：
Paczesny, Sophie
中科院分区：
文献类型：
--
作者：
Han, Yan;Bidgoli, Alan;DePriest, Brittany P.;Mendez, Alejandra;Bijangi-Vishehsaraei, Khadijeh;Perez-Albuerne, Evelio D.;Krance, Robert A.;Renbarger, Jamie;Skiles, Jodi L.;Choi, Sung W.;Liu, Hao;Paczesny, Sophie
目前，没有实验室测试来分层发生鼻窦阻塞综合征（SOS）的风险，这是造血细胞移植（HCT）后的早期内皮并发症。SOS的风险生物标志物尚未在考虑跨机构实践差异的前瞻性队列中得到验证。在这里，我们的目的是用3种蛋白：L-ficolin、透明质酸（HA）和刺激2 （ST2）来定义SOS发生的危险群体。在2017年至2021年期间，我们预计在美国4个中心累积了80名儿科患者。生物标志物通过ELISA盲法检测患者分组，并与HCT后第35天的SOS发生率和HCT后第100天的总生存率（OS）相关。使用回顾性队列确定切点，并应用于前瞻性队列。在前瞻性队列中，HCT后第3天测量的3种生物标志物的组合为SOS发生的风险提供了80% （95% CI 55%-100%）的敏感性和73% （95% CI 62%-83%）的特异性。低L-ficolin患者发生SOS的可能性是其9倍（95% CI 3-32），而高HA和ST2患者发生SOS的可能性是其6.5倍（95% CI 1.9-22.0）和5.5倍（95% CI 2.3-13.1）。这3个指标也预测了较差的第100天OS - L-ficolin: HR， 10.0 (95% CI 2.2 ~ 45.1), P = 0.0002；Ha: hr, 4.1 (95% ci 1.0-16.4), p = 0.031；ST2: HR为3.9 (95% CI 0.9 ~ 16.4), P = 0.04。早在HCT后3天测量的L-ficolin、HA和ST2水平改善了SOS发生和OS的风险分层，并可能指导风险适应的先发制人治疗。ClinicalTrials.gov NCT03132337。国家卫生研究院。
Currently, no laboratory tests exist to stratify for the risk of developing sinusoidal obstruction syndrome (SOS), an early endothelial complication after hematopoietic cell transplantation (HCT). Risk biomarkers of SOS have not been verified in a prospective cohort accounting for differences between practices across institutions. Herein, we aimed to define risk groups for SOS occurrence using 3 proteins: L-ficolin, hyaluronic acid (HA), and stimulation 2 (ST2). Between 2017 and 2021, we prospectively accrued 80 pediatric patients across 4 US centers. Biomarkers were tested by ELISA blind to patient groupings and associated with SOS incidence on day 35 after HCT, and overall survival (OS) on day 100 after HCT. Cutpoints were identified using retrospective cohorts and applied to the prospective cohort. Combination of the 3 biomarkers measured on day 3 after HCT in the prospective cohort provided 80% (95% CI 55%–100%) sensitivity and 73% (95% CI 62%–83%) specificity for risk of SOS occurrence. Patients with low L-ficolin were 9 times (95% CI 3–32) more likely to develop SOS, while patients with high HA and ST2 were 6.5 (95% CI 1.9–22.0) and 5.5 (95% CI 2.3–13.1) times more likely to develop SOS. These 3 markers also predicted worse day 100 OS — L-ficolin: HR, 10.0 (95% CI 2.2–45.1), P = 0.0002; HA: HR, 4.1 (95% CI 1.0–16.4), P = 0.031; and ST2: HR, 3.9 (95% CI 0.9–16.4), P = 0.04. L-ficolin, HA, and ST2 levels measured as early as 3 days after HCT improved risk stratification for SOS occurrence and OS and may guide risk-adapted preemptive therapy. ClinicalTrials.gov NCT03132337. NIH.
登录
查看更多内容
影响因子：
4.8
作者：
Mohty M;Malard F;Abecassis M;Aerts E;Alaskar AS;Aljurf M;Arat M;Bader P;Baron F;Bazarbachi A;Blaise D;Ciceri F;Corbacioglu S;Dalle JH;Dignan F;Fukuda T;Huynh A;Masszi T;Michallet M;Nagler A;NiChonghaile M;Okamoto S;Pagliuca A;Peters C;Petersen FB;Richardson PG;Ruutu T;Savani BN;Wallhult E;Yakoub-Agha I;Duarte RF;Carreras E
通讯作者：
Carreras E
DOI：
10.1016/j.bbmt.2015.07.004
发表时间：
2015-10
期刊：
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
影响因子：
--
作者：
Akil A;Zhang Q;Mumaw CL;Raiker N;Yu J;Velez de Mendizabal N;Haneline LS;Robertson KA;Skiles J;Diaz-Ricart M;Carreras E;Renbarger J;Hanash S;Bies RR;Paczesny S
通讯作者：
Paczesny S
影响因子：
13.5
作者：
MCDONALD, GB;SHARMA, P;THOMAS, ED
通讯作者：
THOMAS, ED
影响因子：
4.3
作者：
Paczesny, Sophie;Hakim, Frances T.;Schultz, Kirk R.
通讯作者：
Schultz, Kirk R.
影响因子：
4.8
作者：
Corbacioglu S;Carreras E;Ansari M;Balduzzi A;Cesaro S;Dalle JH;Dignan F;Gibson B;Guengoer T;Gruhn B;Lankester A;Locatelli F;Pagliuca A;Peters C;Richardson PG;Schulz AS;Sedlacek P;Stein J;Sykora KW;Toporski J;Trigoso E;Vetteranta K;Wachowiak J;Wallhult E;Wynn R;Yaniv I;Yesilipek A;Mohty M;Bader P
通讯作者：
Bader P